29 years after the foundation of the Zur Rose Group in 1993, we are today best positioned in our core European markets in Germany, Switzerland, France and Spain. Every day, our strong team of 2,400 employees are building and defining Europe’s go-to digital health destination.
Find out more about what the decisive levers are and why our equity story is so convincing.
in EUR in Germany
expected as mid-term target
based on adjusted EBITDA
The first phase of the mandatory nationwide rollout of electronic prescriptions (eRx) in Germany started on 1 September 2022. With our number 1 brand DocMorris and its seamless app, we are well prepared for this unique opportunity. Today, eRx online penetration is almost non-existent in the German EUR 50 billion market. However, Sweden has proven that things can be done differently. Here, eRx online penetration has reached 13% in only a few years, and we see the same mid-term potential for the large German market, but with much better starting conditions. While Sweden had to start from scratch, the Zur Rose Group is already active in the German over-the-counter (OTC) market with an online penetration of 23%.
The Zur Rose Group is internationally present with strong brands such as DocMorris, Germany’s best-known healthcare platform. Since our founding, we have gained major experience in the e-commerce sector in dealing with complex regulatory systems, as well as in building relevant industry partnerships. Today, we serve more than 11 million active customers who are at the heart of everything we do.
Technology is a key enabler for our future success. Together with IBM, one of the world’s largest information technology companies, we are actively participating in designing the German eRx system – providing valuable insights for the development of the underlying server infrastructure.
Our experienced Chief Technology Officer Madhu Nutakki, in collaboration with our entire Executive Board, continues to drive our development as a technology company.
From 2017 to 2021 the focus of the Zur Rose Group was on growth – not only in terms of revenue, but also in regards to our active customer base. We invested in recruiting the best talent, as well as in technology, eRx readiness, and internationalisation, all of which set the stage for us to become the leader in our key markets. For the remainder of 2022 and looking ahead to 2023, our full focus is on accelerated break-even. Reducing complexity and clearly focusing on operational excellence, as well as on our core business, are major pillars of our CHF 130 million break-even programme. This will lead to an adjusted EBITDA break-even already in 2023, which is independent from eRx. It will be the foundation for our profitable growth from 2024 onwards. Beyond the mandatory introduction of eRx in Germany, we are continuing to expand our digital health ecosystem.
Break-even programme with an expected positive EBITDA impact of CHF 130 million by 2023 compared to EBITDA 2021: